Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment

BACKGROUND: Predictive biomarkers are needed to identify oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER + /HER2-) metastatic breast cancer (MBC) patients who would likely benefit from cyclin-dependent kinase 4 and 6 inhibitors combined with endocrine therapy. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Cheng, Hu, Shihui, Xu, Xiaoping, Zhang, Yongping, Wang, Biyun, Song, Shaoli, Yang, Zhongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419349/
https://www.ncbi.nlm.nih.gov/pubmed/36028895
http://dx.doi.org/10.1186/s13058-022-01555-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419349/
https://www.ncbi.nlm.nih.gov/pubmed/36028895
http://dx.doi.org/10.1186/s13058-022-01555-7

Ejemplares similares